Niemann–Pick disease
Niemann–Pick disease | |
---|---|
Child with Niemann-Pick Disease | |
Pronunciation | |
Specialty | Medical genetics |
Niemann–Pick disease (NP), also known as acid sphingomyelinase deficiency, is a group of rare genetic diseases of varying severity. These are inherited
These disorders involve the dysfunctional metabolism of
Signs and symptoms
Symptoms are related to the organs in which sphingomyelin accumulates. Enlargement of the liver and spleen (hepatosplenomegaly) may cause reduced appetite, abdominal distension, and pain. Enlargement of the spleen (splenomegaly) may also cause low levels of platelets in the blood (thrombocytopenia).[citation needed]
Accumulation of sphingomyelin in the central nervous system (including the cerebellum) results in unsteady gait (ataxia), slurring of speech (dysarthria), and difficulty swallowing (dysphagia). Basal ganglia dysfunction causes abnormal posturing of the limbs, trunk, and face (dystonia). Upper brainstem disease results in impaired voluntary rapid eye movements (supranuclear gaze palsy). More widespread disease involving the cerebral cortex and subcortical structures causes gradual loss of intellectual abilities, causing dementia and seizures.[citation needed]
Bones also may be affected, with the disease causing enlarged
Causes
Mutations in the
Mutations in
Type D originally was separated from type C to delineate a group of patients with otherwise identical disorders who shared a common Nova Scotian ancestry. Patients in this group are known to share a specific mutation in the NPC1 gene, so NPC is used for both groups. Before the molecular defects were described, the terms "Niemann–Pick type I" and "Niemann–Pick type II" were proposed to separate the high- and low-sphingomyelin forms of the disease in the early 1980s.[citation needed]
Niemann–Pick disease is inherited in an
Pathophysiology
Niemann–Pick diseases are a subgroup of
]In the classic infantile type-A variant, a
Diagnosis
For type A and B, levels of sphingomylinase can be measured from a blood sample. To diagnose type C, a skin sample can help determine whether the transporter is affected via the Filipin test which detects build-up of unesterified cholesterol via fluorescent staining.[6] [7]
Classification
The four types of Niemann–Pick disease are divided into categories. Patients with ASM deficiency are classified into types A and B. Type A patients exhibit hepatosplenomegaly in infancy and profound central nervous system involvement, and are unable to survive beyond two years of age. Type B patients also show hepatosplenomegaly and pathologic alterations of their lungs, but usually without the involvement of their central nervous system. Some can develop significant life-threatening complications, including liver failure, hemorrhage, oxygen dependency, pulmonary infections, and splenic rupture. Some develop coronary arterial or valvular heart disease. In a longitudinal natural history study, nearly 20% of the patients died. For those classified into type C, they may have mild hepatosplenomegaly, but their central nervous system is profoundly affected.[8]
- Niemann–Pick disease, SMPD1-associated, which includes types A and B
- Niemann–Pick disease type A: classic infantile
- Niemann–Pick disease type B: visceral
- Niemann–Pick disease, type C: subacute/juvenile, includes types C1 (95% of type C) and C2. Type C is the most common form of the disease[3] Type C2 is a rare form of the disease.[9]
Niemann–Pick disease type D (or Nova Scotia form) is now believed to be the same condition as Niemann–Pick disease type C.[10] Two poorly characterized forms of Niemann–Pick disease have also been described as types E and F.[11]
Treatment
No specific treatment is known for type A, but symptoms are treated.[citation needed]
In adult patients with type B, physicians try to keep cholesterol levels down to normal levels. If statins are used, they monitor liver function. If the spleen is enlarged and platelet levels low, acute episodes of bleeding may require transfusions of blood products. If they have symptoms of interstitial lung disease, they may need oxygen.[12]
Anecdotally, organ transplant has been attempted with limited success. Future prospects include enzyme replacement and gene therapy. Bone marrow transplant has been tried for type B.[8]
In January 2009, Actelion announced the drug miglustat (Zavesca) had been approved in the European Union for the treatment of progressive neurological manifestations in adult patients and pediatric patients with NPC. The drug is available to patients in the United States on an experimental basis. In March 2010, the FDA requested additional preclinical and clinical information regarding Zavesca from Actelion before making a final decision on approving the drug in the United States for NPC.[13]
Olipudase alfa (Xenpozyme) was approved for medical use in Japan in March 2022.[14]
Prognosis
Highly variable, infantile neurovisceral Niemann Pick disease (Type A ASMD) is usually fatal before 3 years of age. In Type B, severity is highly variable, and many patients live well into adulthood and may reach a normal lifespan. Diagnoses have been made in the 7th decade of life. [15][16][17]
Type C is an entirely different disorder, which also has a highly variable prognosis.[citation needed]
Incidence
The incidence among Ashkenazi Jews is estimated to be about one in 40,000 for type A of Niemann–Pick disease.[3] The incidence of both Niemann–Pick disease types A and B in all other populations is estimated to be one in 250,000.[3] The incidence of Niemann–Pick disease type C is estimated to be one in 150,000.[3]
History
In 1961, the classification of Niemann–Pick disease into types A, B, and C was introduced, and also contained a type D,[21][22] called the "Nova Scotian type". Genetic studies showed that type D is caused by the same gene as type C1, and the type D designation is no longer used.[3]
Research
Research has been ongoing to better understand the disease and treatments for it, however at present there is no cure. [23]
Pathology
The loss of
Curiously, in 2011
Other studies have uncovered small molecules which inhibit the receptor and may be a potential therapeutic strategy.[27]
Treatments under investigation
Experimental use of arimoclomol
In 2014, the
Experimental use of 2-hydroxypropyl-β-cyclodextrin
Researchers at the University of Arizona first proposed the use of 2-hydroxypropyl-β-cyclodextrins for the treatment of Niemann–Pick Type C1 in 2001.[31] Researchers noted that HPBCDs, with varying levels of 2-hydroxypropyl substitution, had effects in delaying neurological symptoms and in decreasing liver cholesterol storage in a Niemann–Pick mouse model. Later, researchers at the University of Texas Southwestern Medical Center found that when Niemann–Pick type C mice were injected with 2-hydroxypropyl-β-cyclodextrin (HPbCD) when they were seven days old, they showed marked improvement in liver function, much less neurodegeneration, and ultimately, they lived longer lives than the mice that did not receive this treatment. These results suggest HPbCD acutely reverses the storage defect seen in NPC.[32]
In April 2011, the U.S. National Institutes of Health, in collaboration with the Therapeutics for Rare and Neglected Diseases Program,[33] announced they were developing a clinical trial using HPbCD for Niemann–Pick type C1 patients. A clinical trial conducted by Vtesse, LLC began in January 2013, and was completed in March 2017.[34]
On April 26, 2013, the European Medicines Agency granted International Niemann–Pick Disease Alliance, the United Kingdom, orphan designation for HPbCD for the treatment of Niemann–Pick disease, type C.[35]
Gene therapy
See also
- Gaucher's disease
- Lysosomal storage disease
- Medical genetics of Ashkenazi Jews
- Niemann–Pick disease, type C
References
- ^ "Niemann–Pick". Oxford English Dictionary (Online ed.). Oxford University Press. (Subscription or participating institution membership required.)
- ISBN 978-0-7216-2921-6.
- ^ a b c d e f g "Neimann-Pick Disease". Genetics Home Reference. NIH. January 2008. Retrieved 2 October 2012.
- ^ "Niemann-Pick disease". Genetics Home Reference.
- ^ "Niemann-Pick - Symptoms and causes". Mayo Clinic.
- ^ "Niemann-Pick - Diagnosis and treatment - Mayo Clinic". Mayo Clinic.
- PMID 25665455.
- ^ PMID 25987176.
- ^ Sphingomyelinase Deficiency at eMedicine
- ^ "Niemann Pick Disease Type C". National Organization for Rare Disorders.
- ^ "NIEMANN-PICK DISEASE, TYPE B". OMIM. 9 April 2019. 607616.
- ^ Sphingomyelinase Deficiency~treatment at eMedicine
- ^ "Actelion Pharmaceuticals Ltd (CH) - Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease" (Press Release). Drugs.com. 9 March 2010.
- ^ "Xenpozyme (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency" (Press release). Sanofi. 28 March 2022. Retrieved 20 May 2022.
- ^ Uz E, Cipil H, Turgut FH, Kaya A, Kargili A, Bavbek N, Ali A, Ali K. Niemann-Pick disease type B presenting with hepatosplenomegaly and thrombocytopenia. South Med J. 2008 Nov;101(11):1188. doi: 10.1097/SMJ.0b013e3181836b4c. PMID: 19088546.
- ^ McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med 2013;15:618–623.
- ^ Cassiman D, Packman S, Bembi B, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (NiemannPick disease type B and B variant): Literature review and report of new cases. Mol Genet Metab 2016;118:206–213.
- Who Named It?
- ^ Niemann, A. (1914). "Ein unbekanntes Krankheitsbild" [An unknown disease picture]. Jahrbuch für Kinderheilkunde. Neue Folge (in German). 79: 1–10.
- ^ Pick, L. (1926). "Der Morbus Gaucher und die ihm ähnlichen Krankheiten (die lipoidzellige Splenohepatomegalie Typus Niemann und die diabetische Lipoidzellenhypoplasie der Milz)" [Gaucher's disease and similar diseases (type Niemann lipoid cell splenohepatomegaly and spleen diabetic lipoid cell hypoplasia)]. Ergebnisse der Inneren Medizin und Kinderheilkunde (in German). 29: 519–627.
- S2CID 22103848.
- ^ Online Mendelian Inheritance in Man (OMIM): Niemann–Pick Disease, Type C1; NPC1 - 257220
- PMID 20301473, retrieved 2023-07-30
- ^ S2CID 26878522.
- PMID 22956843.
- PMID 21866103.
- PMID 21866101.
- ^ "European Medicines Agency - - EU/3/14/1376". www.ema.europa.eu. 2018-09-17.
- ^ "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov.
- ^ "Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 14 April 2021.
- PMID 11787939.
- PMID 19171898.
- ^ "Therapeutics for Rare and Neglected Diseases Program". U.S. National Institutes of Health. November 2017.
- ^ "Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease". ClinicalTrials.gov. NIH. 19 July 2021. Retrieved 10 January 2022.
- ^ "EU/3/13/1124 | European Medicines Agency". European Medicines Agency. 17 September 2018. Retrieved April 16, 2021.
- PMID 29878115.
- PMID 34407999.
- PMID 31434754.
- Attribution
- This article incorporates public domain text from The U.S. National Library of Medicine